Table 1.
Peptidomimetics that affect peptide-based quorum sensing system.
| Name | Sequence* | Agonism | Antagonism | References |
|---|---|---|---|---|
| Agr system | ||||
| AIP III | IN(CDFLL) | AgrC III | Tal-Gan et al., 2013 | |
| AIP III DI1 | DIN(CDFLL) | AgrC I-IV | ||
| AIP III DN2 | IDN(CDFLL) | AgrC I-IV | ||
| AIP III DC3 | IN(DCDFLL) | Low activity | ||
| AIP III DD4 | IN(CDDFLL) | AgrC I, II, IV | ||
| AIP III DF5 | IN(CDDFLL) | Low activity | ||
| AIP III DL6 | IN(CDFDLL) | AgrC II | Low activity | |
| AIP III DL7 | IN(CDFLDL) | AgrC III | AgrC I, II, IV | |
| tAIP III D2A | Ac-(CAFLL) | AgrC I-IV | ||
| tAIP III D2A/F3Y | Ac-(CAYLL) | AgrC I-IV | ||
| tAIP IIID2A/F3W | Ac-(CAWLL) | AgrC I-IV | ||
| AIP II | GVNA(CSSLF) | AgrC II | Tal-Gan et al., 2016; Vasquez et al., 2017 | |
| tAIP II | Ac-(CSSLF) | AgrC I-IV | ||
| n5FF | Ac-(C5MeFF) | AgrC I-IV | ||
| n6FF | Ac-(C6MeFF) | AgrC I-IV | ||
| n7FF | Ac-(C7MeFF) | AgrC I-IV | ||
| Peptide A3 | WFAKMWK | Inactive | Karathanasi et al., 2018 | |
| A3 | Analogous peptoid | AgrC I | ||
| Peptide D3 | WFKKMWK | Inactive | ||
| D3 | Analogous peptoid | AgrC I | ||
| Peptide G3 | WFGKMWK | Inactive | ||
| G3 | Analogous peptoid | AgrC I | ||
| AIP II | GVNA(CSSLF) | AgrC II | Vasquez and Blackwell, 2019 | |
| tAIP II | Ac-(CSSLF) | AgrC I-IV | ||
| n7OFF | Ac-(C7Me2OFF) | Low activity | ||
| Bnc3 | Phe-Ac-(C7Me2OcpA3fF) | AgrC I-IV | ||
| Pentyl-n7OCpa(3fF) | AgrC I-IV | |||
| Bn-n7OCpa(3C1F) | AgrC I-IV | |||
| Bn-n7OCpa(3fF)-am | AgrC III | |||
| Bn-n7OCpa(3fF)-es | AgrC III | |||
| Decanoyl-ornithyl-ornithyl-dodecanoyl-ornithyl-amide | C10OOc12O (Lipopeptide) | Agr-MRSA | Hershkovits et al., 2019 | |
| AIP II | NASKYNP(CSNYL) | AgrC II | AgrC I | West et al., 2021 |
| AIP II DK4 | NASDKYNP(CSNYL) | Low activity | ||
| AIP II DS9 | NASKYNP(CDSNYL) | Inactive | ||
| AIP II DN10 | NASKYNP(CSDNYL) | Inactive | ||
| AIP III | NAAKYNP(CASYL) | AgrC III | AgrC I | |
| AIP III DK4 | NAADKYNP(CASYL) | AgrC III | ||
| AIP III DA9 | NAAKYNP(CDASYL) | Inactive | ||
| AIP II DS10 | NAAKYNP(CADSYL) | AgrC III | ||
| Com system | ||||
| CSP1 | EMRLSKFFRDFILQRKK | ComD1 | Yang et al., 2017 | |
| Low activity on ComD2 | ||||
| CSP1-DS5 | EMRLDSKFFRDFILQRKK | ComD1 | ||
| CSP1-DQ14 | EMRLSKFFRDFILDQRKK | ComD1 | ||
| CSP1-DR15 | EMRLSKFFRDFILQDRKK | ComD1 | ||
| CSP1-DK16 | EMRLSKFFRDFILQRDKK | ComD1 | ||
| CSP1-DK17 | EMRLSKFFRDFILQRKDK | ComD1 | ||
| CSP2 | EMRISRIILDFLFLRKK | ComD2 | ||
| Low activity on ComD1 | ||||
| CSP2-DF13 | EMRISRIILDFLDFLRKK | ComD2 | ||
| CSP2-DL14 | EMRISRIILDFLFDLRKK | ComD2 | ||
| CSP2-DR15 | EMRISRIILDFLFLDRKK | ComD2 | ||
| CSP2-DK16 | EMRISRIILDFLFLRDKK | ComD2 | ||
| CSP2-DK17 | EMRISRIILDFLFLRKDK | ComD2 | ||
| CSP2-E1A DD10 | AMRISRIILDDFLFLRKK | ComD2 | ||
| CSP2-E1A I4NvaD10L14Q | AMRNvaSRIILDFLFQRKK | ComD1 and 2 | Koirala and Tal-Gan, 2020 | |
| CSP1-E1A-cyc(Dap6E10) | AMRLS(DapFFRE)FILQRKK | ComD1 and 2 | Yang et al., 2020 | |
| CSP1-E1A-desK16 K17cyc(Dap6E10) | AMRLS(DapFFRE)FILQR | ComD1 and 2 | ||
| 18-CSP | SGSLSTFFRLFNRSFTQA | ComD | Bikash et al., 2018 | |
| 18-CSP(DL4) | SGSDLSTFFRLFNRSFTQA | ComD | ||
| 18-CSP(DS1) | DSGSLSTFFRLFNRSFTQA | ComD | ||
| P3 | 18-CSP-des-S1G2-N-Me-S3 | ComD | Bikash and Tal-Gan, 2019 | |
| Fsr system | ||||
| GBAP | QN(SPNIFGQWM) | FsrC | McBrayer et al., 2017 | |
| GBAP-DQ1 | DQN(SPNIFGQWM) | FsrC | ||
| GBAP-DN2 | QDN(SPNIFGQWM) | FsrC | ||
| Ac-GBAP | Ac-QN(SPNIFGQWM) | FsrC | ||
| Ac-GBAP-DesQ1 | Ac-N(SPNIFGQWM) | FsrC | ||
| Ac-GBAP-desQ1N2 | Ac-(SPNIFGQWM) | FsrC | ||
| GBAP-N5[YBzl]M11A | QN(SP-YBzl-IFGQWA) | FsrC | McBrayer et al., 2018 | |
| Ac-GBAP-Des (Q1N2)[N-MeF7] | Ac-(SPNI[NMeF7]GQWM) | FsrC | McBrayer et al., 2019 | |
| ZBzl-YAA5911 | Z-QN(SP[YBzl]IFGQWM) | FsrC | Nakayama et al., 2013 | |
| RRNPP pathway system | ||||
| PapR7 | ADLPFEF | PlcR | Yehuda et al., 2018 | |
| PapR7-DA1 | DADLPFEF | PlcR | ||
| PapR7-DE6 | ADLPFDEF | PlcR | ||
| PapR7-DF7 | ADLPFEDF | PlcR | ||
t, truncated or lacking an N-terminal exocyclic tail; Agr, accessory gene regulator; Com, competence operon; Dap, 2,3-diaminopropionic acid; Fsr, system regulator; Nva, norvaline; and RRNPP, pathway of response regulators
*
Macrocyclic structures are indicated in parentheses when necessary.